| |
|
|
TO BOARD OF DIRECTORS and Partner at Montgomery Securities MADISON, Wisconsin--January 2000--SLIL Biomedical Corp. announced the addition of Janice M. LeCocq, Ph.D., to its Board of Directors. Dr. LeCocq has over twenty years of experience in corporate finance and management in the life sciences industry. Dr. LeCocq co-founded and currently serves as Managing Partner of Collins Mabry & Co., L.L.C., a Florida based firm that provides consulting and advisory services to investors and entrepreneurs in the life sciences and the health care industry. She is the former Chair and Chief Executive Officer of Gryphon Sciences, a biotechnology company commercializing chemical protein synthesis technology. Prior to that, Dr. LeCocq served as Executive Vice President of Finance and Administration for ICOS Corporation, a biopharmaceutical company. She was previously a General Partner in Corporate Finance, as well as a biotechnology analyst at Montgomery Securities, an investment banker for emerging growth companies. She also serves as a Director of the Nidus Center for Scientific Enterprise and has been a Director of ICOS Corporation, Hyseq and Molecular Dynamics. Dr. LeCocq holds a doctorate in Medical Anthropology and a bachelor’s degree in Human Biology from Stanford University. SLIL Biomedical Corp. is an early-stage drug discovery company focused on developing new treatments to fight cancer. SLIL is a leader in the development of novel polyamine analogs as anti-cancer agents and has proprietary Tumor Targeting and Delivery technologies (TTD™). The Company currently has a pipeline of 16 lead compounds from these technologies. SLIL also has an exclusive license to the Sequential Pathogenesis Model technology from the University of California-San Francisco that has far reaching potential diagnostic and prognostic applications for cancer and other diseases. SLIL has its headquarters and drug discovery activities in Madison, Wisconsin and additional research facilities, dedicated to the Sequential Pathogenesis Model technology, in Menlo Park, California. SOURCE: SLIL Biomedical Corp. Contact: Marla K. Johnson SLIL Biomedical Corp.
|